FDA Approves First Non-Antipsychotic Drug for Alzheimer's Agitation

FDA Approves First Non-Antipsychotic Drug for Alzheimer's Agitation

Summary

Oral NMDA receptor antagonist gets an expanded indication

Original reporting

Open original source

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Related coverage